

WuXi Bio, NBE-Therapeutics announce ADC partnership

10 April 2019 | News | By Sonali Wankhade

The partnership with WuXi Biologics will enable the supply of NBE's product for clinical trials under Investigational New Drug (IND) applications worldwide



WuXi Biologics ("WuXi Bio"), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and NBE-Therapeutics (NBE), a privately owned Swiss biotech company developing best-in-class, next-generation antibody-drug conjugate (ADC) products, announced a comprehensive development and manufacturing partnership for NBE's first ADC lead product NBE-002 (anti-ROR1).

NBE-002 is a best-in-class immune-stimulatory ADC (iADC) treatment against the ROR1 cancer target and is planned to enter into clinical trials in mid 2020 in triple negative breast cancer and other indications.

NBE-Therapeutics develops next-generation iADC products with the aim to improve the outcome for cancer patients, as it continues to develop iADCs based on its proprietary technology platforms. With its proprietary SMAC-Technology™ to generate site-specifically conjugated ADCs and its proprietary highly-potent anthracycline toxin platform, NBE has the ability to develop highly targeted treatments with long-lasting anti-tumor immunity.

The partnership with WuXi Biologics will enable the supply of NBE's product for clinical trials under Investigational New Drug (IND) applications worldwide. With the establishment of state-of-the-art integrated biologics solution center, WuXi Biologics provides comprehensive one-stop service to global partners for antibodies, ADC drug substances and drug products.